Natriuretic peptide drug leads from snake venom

Toxicon

Volumn 59, Issue 4, 2012, Pages 434-445

  Vink, S ^a   Jin, A H ^a   Poth, K J ^a   Head, G A ^b   Alewood, P F ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

CGMP; Guanylyl cyclase; Heart failure; Natriuretic peptide; TNP

Indexed keywords

ANARITIDE; ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR ALPHA; BRAIN NATRIURETIC PEPTIDE; CHIMERIC NATRIURETIC PEPTIDE; CYCLIC GMP; GLYCERYL TRINITRATE; HUMAN BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE RECEPTOR A; NATRIURETIC PEPTIDE RECEPTOR B; NATRIURETIC PEPTIDE RECEPTOR C; NATRIURETIC PEPTIDE TYPE C; NESIRITIDE; SNAKE VENOM; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; ACUTE HEART INFARCTION; ASSAY; AUTOCRINE EFFECT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR EFFECT; CONGESTIVE HEART FAILURE; CRYSTAL STRUCTURE; DENDROASPIS; DIURESIS; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG HALF LIFE; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPOTENSION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; NATRIURESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; ORGAN BATH ASSAY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN STRUCTURE; RENAL PROTECTION; REPTILE; REVIEW; SEQUENCE ALIGNMENT; SIDE EFFECT; SMOOTH MUSCLE RELAXATION; UNSPECIFIED SIDE EFFECT; VAGUS REFLEX; VASODILATATION;

ANIMALS; ATRIAL NATRIURETIC FACTOR; DIURESIS; ELAPID VENOMS; HEART FAILURE; HUMANS; NATRIURESIS; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDE, C-TYPE; PEPTIDES; RECEPTORS, ATRIAL NATRIURETIC FACTOR; SNAKE VENOMS;

AMPHIBIA; CROCODYLUS NILOTICUS; DENDROASPIS; DENDROASPIS ANGUSTICEPS; MAMMALIA; OXYURANUS MICROLEPIDOTUS; RATTUS; REPTILIA; VERTEBRATA;

EID: 84857059733     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2010.12.001     Document Type: Review

References (124)

1. Ackermann U., Khanna J., Irizawa T.G. Atrial natriuretic factor alters autonomic interactions in the control of heart rate in conscious rats. Can. J. Physiol. Pharmacol. 1988, 66:930-936.
2. Amininasab M., Elmi M.M., Endlich N., Endlich K., Parekh N., Naderi-Manesh H., Schaller J., Mostafavi H., Sattler M., Sarbolouki M.N., Muhle-Goll C. Functional and structural characterization of a novel member of the natriuretic family of peptides from the venom of Pseudocerastes persicus. FEBS Lett. 2004, 557:104-108.
3. Ardaillou N., Nivez M.P., Ardaillou R. Stimulation of cyclic GMP synthesis in human cultured glomerular cells by atrial natriuretic peptide. FEBS Lett. 1986, 204:177-182.
4. Atlas S.A., Kleinert H.D., Camargo M.J., Januszewicz A., Sealey J.E., Laragh J.H., Schilling J.W., Lewicki J.A., Johnson L.K., Maack T. Purification, sequencing and synthesis of natriuretic and vasoactive rat atrial peptide. Nature 1984, 309:717-719.
5. Bando M., Ishii Y., Sugiyama Y., Kitamura S. Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale. Respir. Med. 1999, 93:507-514.
6. Barbouche R., Marrakchi N., Mansuelle P., Krifi M., Fenouillet E., Rochat H., el Ayeb M. Novel anti-platelet aggregation polypeptides from Vipera lebetina venom: isolation and characterization. FEBS Lett. 1996, 392:6-10.
7. Bargnoux A.S., Klouche K., Fareh J., Barazer I., Villard-Saussine S., Dupuy A.M., Leray-Moragues H., Giuliani I., Canaud B., Cristol J.P. Prohormone brain natriuretic peptide (proBNP), BNP and N-terminal-proBNP circulating levels in chronic hemodialysis patients. Correlation with ventricular function, fluid removal and effect of hemodiafiltration. Clin. Chem. Lab. Med. 2008, 46:1019-1024.
8. Bennett B.D., Bennett G.L., Vitangcol R.V., Jewett J.R., Burnier J., Henzel W., Lowe D.G. Extracellular domain-IgG fusion proteins for three human natriuretic peptide receptors. Hormone pharmacology and application to solid phase screening of synthetic peptide antisera. J. Biol. Chem. 1991, 266:23060-23067.
9. Brandt R.R., Wright R.S., Redfield M.M., Burnett J.C. Atrial natriuretic peptide in heart failure. J. Am. Coll. Cardiol. 1993, 22:86A-92A.
10. Brunner-La Rocca H.P., Kaye D.M., Woods R.L., Hastings J., Esler M.D. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J. Am. Coll. Cardiol. 2001, 37:1221-1227.
11. Burnett J.C., Kao P.C., Hu D.C., Heser D.W., Heublein D., Granger J.P., Opgenorth T.J., Reeder G.S. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986, 231:1145-1147.
12. Cataliotti A., Schirger J.A., Martin F.L., Chen H.H., McKie P.M., Boerrigter G., Costello-Boerrigter L.C., Harty G., Heublein D.M., Sandberg S.M., James K.D., Miller M.A., Malkar N.B., Polowy K., Burnett J.C. Oral human brain natriuretic peptide activates cyclic guanosine 3',5'-monophosphate and decreases mean arterial pressure. Circulation 2005, 112:836-840.
13. Chang M.S., Lowe D.G., Lewis M., Hellmiss R., Chen E., Goeddel D.V. Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases. Nature 1989, 341:68-72.
14. Chen H.H., Lainchbury J.G., Burnett J.C. Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide. J. Am. Coll. Cardiol. 2002, 40:1186-1191.
15. Chinkers M., Garbers D.L. The protein kinase domain of the ANP receptor is required for signaling. Science 1989, 245:1392-1394.
16. Chinkers M., Garbers D.L., Chang M.S., Lowe D.G., Chin H.M., Goeddel D.V., Schulz S. A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature 1989, 338:78-83.
17. Cody R.J., Atlas S.A., Laragh J.H., Kubo S.H., Covit A.B., Ryman K.S., Shaknovich A., Pondolfino K., Clark M., Camargo M.J., et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J. Clin. Invest. 1986, 78:1362-1374.
18. Colucci W.S., Elkayam U., Horton D.P., Abraham W.T., Bourge R.C., Johnson A.D., Wagoner L.E., Givertz M.M., Liang C.S., Neibaur M., Haught W.H., LeJemtel T.H. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N. Engl. J. Med. 2000, 343:246-253.
19. Cowie M.R., Struthers A.D., Wood D.A., Coats A.J., Thompson S.G., Poole-Wilson P.A., Sutton G.C. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997, 350:1349-1353.
20. Craik D., Munro S., Nielsen K., Shehan P., Tregear G., Wade J. The conformation of porcine-brain natriuretic peptide by two-dimensional NMR spectroscopy. Eur. J. Biochem. 1991, 201:183-190.
21. Currie M.G., Geller D.M., Cole B.R., Boylan J.G., YuSheng W., Holmberg S.W., Needleman P. Bioactive cardiac substances: potent vasorelaxant activity in mammalian atria. Science 1983, 221:71-73.
22. D'Souza S.P., Davis M., Baxter G.F. Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacol. Ther. 2004, 101:113-129.
23. Dao Q., Krishnaswamy P., Kazanegra R., Harrison A., Amirnovin R., Lenert L., Clopton P., Alberto J., Hlavin P., Maisel A.S. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J. Am. Coll. Cardiol. 2001, 37:379-385.
24. de Bold A.J., Borenstein H.B., Veress A.T., Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981, 28:89-94.
25. Demain A.L., Vaishnav P. Production of recombinant proteins by microbes and higher organisms. Biotechnol. Adv. 2009, 27:297-306.
26. Dickey D.M., Burnett J.C., Potter L.R. Novel bifunctional natriuretic peptides as potential therapeutics. J. Biol. Chem. 2008, 283:35003-35009.
27. Evangelista J.S., Martins A.M., Nascimento N.R., Sousa C.M., Alves R.S., Toyama D.O., Toyama M.H., Evangelista J.J., Menezes D.B., Fonteles M.C., Moraes M.E., Monteiro H.S. Renal and vascular effects of the natriuretic peptide isolated from Crotalus durissus cascavella venom. Toxicon 2008, 52:737-744.
28. Fifer M.A., Molina C.R., Quiroz A.C., Giles T.D., Herrmann H.C., De Scheerder I.R., Clement D.L., Kubo S., Cody R.J., Cohn J.N., et al. Hemodynamic and renal effects of atrial natriuretic peptide in congestive heart failure. Am. J. Cardiol. 1990, 65:211-216.
29. Fry B.G., Vidal N., Norman J.A., Vonk F.J., Scheib H., Ramjan S.F., Kuruppu S., Fung K., Hedges S.B., Richardson M.K., Hodgson W.C., Ignjatovic V., Summerhayes R., Kochva E. Early evolution of the venom system in lizards and snakes. Nature 2006, 439:584-588.
30. Fry B.G., Wickramaratana J.C., Lemme S., Beuve A., Garbers D., Hodgson W.C., Alewood P. Novel natriuretic peptides from the venom of the inland taipan (Oxyuranus microlepidotus): isolation, chemical and biological characterisation. Biochem. Biophys. Res. Commun. 2005, 327:1011-1015.
31. Fuller F., Porter J.G., Arfsten A.E., Miller J., Schilling J.W., Scarborough R.M., Lewicki J.A., Schenk D.B. Atrial natriuretic peptide clearance receptor. Complete sequence and functional expression of cDNA clones. J. Biol. Chem. 1988, 263:9395-9401.
32. Grines C.L. Safety and effectiveness of dofetilide for conversion of atrial fibrillation and nesiritide for acute decompensation of heart failure: a report from the cardiovascular and renal advisory panel of the Food and Drug Administration. Circulation 2000, 101:E200-E201.
33. Hata N., Seino Y., Tsutamoto T., Hiramitsu S., Kaneko N., Yoshikawa T., Yokoyama H., Tanaka K., Mizuno K., Nejima J., Kinoshita M. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study. Circ. J. 2008, 72:1787-1793.
34. He X., Chow D., Martick M.M., Garcia K.C. Allosteric activation of a spring-loaded natriuretic peptide receptor dimer by hormone. Science 2001, 293:1657-1662.
35. He X.L., Dukkipati A., Garcia K.C. Structural determinants of natriuretic peptide receptor specificity and degeneracy. J. Mol. Biol. 2006, 361:698-714.
36. He X.L., Dukkipati A., Wang X., Garcia K.C. A new paradigm for hormone recognition and allosteric receptor activation revealed from structural studies of NPR-C. Peptides 2005, 26:1035-1043.
37. Hobbs F.D., Davis R.C., Roalfe A.K., Hare R., Davies M.K., Kenkre J.E. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ 2002, 324:1498.
38. Holmes S.J., Espiner E.A., Richards A.M., Yandle T.G., Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J. Clin. Endocrinol. Metab. 1993, 76:91-96.
39. Hughes A., Thom S., Goldberg P., Martin G., Sever P. Direct effect of alpha-human atrial natriuretic peptide on human vasculature in vivo and in vitro. Clin. Sci. 1988, 74:207-211.
40. Hunt P.J., Espiner E.A., Nicholls M.G., Richards A.M., Yandle T.G. Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man. J. Clin. Endocrinol. Metab. 1996, 81:3871-3876.
41. Hunt P.J., Yandle T.G., Nicholls M.G., Richards A.M., Espiner E.A. The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem. Biophys. Res. Commun. 1995, 214:1175-1183.
42. Inooka H., Kikuchi T., Endo S., Ishibashi Y., Wakimasu M., Mizuta E. Conformation in solution of porcine brain natriuretic peptide determined by combined use of nuclear magnetic resonance and distance geometry. Eur. J. Biochem. 1990, 193:127-134.
43. Johns D.G., Ao Z., Heidrich B.J., Hunsberger G.E., Graham T., Payne L., Elshourbagy N., Lu Q., Aiyar N., Douglas S.A. Dendroaspis natriuretic peptide binds to the natriuretic peptide clearance receptor. Biochem. Biophys. Res. Commun. 2007, 358:145-149.
44. Kambayashi Y., Nakajima S., Ueda M., Inouye K. A dicarba analog of beta-atrial natriuretic peptide (beta-ANP) inhibits guanosine 3',5'-cyclic monophosphate production induced by alpha-ANP in cultured rat vascular smooth muscle cells. FEBS Lett. 1989, 248:28-34.
45. Kangawa K., Matsuo H. Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP). Biochem. Biophys. Res. Commun. 1984, 118:131-139.
46. Kawakoshi A., Hyodo S., Nozaki M., Takei Y. Identification of a natriuretic peptide (NP) in cyclostomes (lamprey and hagfish): CNP-4 is the ancestral gene of the NP family. Gen. Comp. Endocrinol. 2006, 148:41-47.
47. Kenny A.J., Bourne A., Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem. J. 1993, 291(Pt 1):83-88.
48. Kinnunen P., Vuolteenaho O., Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 1993, 132:1961-1970.
49. Kobayashi Y., Ohkubo T., Kyogoku Y., Koyama S., Kobayashi M., Go N. The conformation of alpha-human atrial natriuretic polypeptide in solution. J. Biochem. 1988, 104:322-325.
50. Koh G.Y., Nussenzveig D.R., Okolicany J., Price D.A., Maack T. Dynamics of atrial natriuretic factor-guanylate cyclase receptors and receptor-ligand complexes in cultured glomerular mesangial and renomedullary interstitial cells. J. Biol. Chem. 1992, 267:11987-11994.
51. Komatsu Y., Nakao K., Itoh H., Suga S., Ogawa Y., Imura H. Vascular natriuretic peptide. Lancet 1992, 340:622.
52. Kort J.J., Koch G. Receptors for atrial natriuretic peptide (ANP) and cyclic GMP responses in HeLa cells. Biochem. Biophys. Res. Commun. 1990, 168:148-154.
53. Lainchbury J.G., Lisy O., Burnett J.C., Meyer D.M., Redfield M.M. Actions of a novel synthetic natriuretic peptide on hemodynamics and ventricular function in the dog. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002, 282:R993-R998.
54. Lee C.Y., Burnett J.C. Natriuretic peptides and therapeutic applications. Heart Fail. Rev. 2007, 12:131-142.
55. Lee C.Y., Chen H.H., Lisy O., Swan S., Cannon C., Lieu H.D., Burnett J.C. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J. Clin. Pharmacol. 2009, 49:668-673.
56. Lee J., Kim S.W. Dendroaspis natriuretic peptide administered intracerebroventricularly increases renal water excretion. Clin. Exp. Pharmacol. Physiol. 2002, 29:195-197.
57. Lieu H., Goldsmith S., Neutal J., Massie B., Burnett J. Initial observations of intravenous CD-NP, chimeric natriuretic peptide, on renal functions in chronic heart failure patients. J. Card. Fail. 2009, 15:S77.
58. Lisy O., Huntley B.K., McCormick D.J., Kurlansky P.A., Burnett J.C. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J. Am. Coll. Cardiol. 2008, 52:60-68.
59. Lisy O., Jougasaki M., Heublein D.M., Schirger J.A., Chen H.H., Wennberg P.W., Burnett J.C. Renal actions of synthetic dendroaspis natriuretic peptide. Kidney Int. 1999, 56:502-508.
60. Lisy O.J., Chen H.H., Burnett J.C. Cardiorenal actions of a new designer natriuretic peptide CD-NP in experimental heart failure. J. Am. Coll. Cardiol. 2009, 53:A149.
61. Lowe D.G. Human natriuretic peptide receptor-A guanylyl cyclase is self-associated prior to hormone binding. Biochem. (Mosc.) 1992, 31:10421-10425.
62. Lowe D.G., Chang M.S., Hellmiss R., Chen E., Singh S., Garbers D.L., Goeddel D.V. Human atrial natriuretic peptide receptor defines a new paradigm for second messenger signal transduction. EMBO J. 1989, 8:1377-1384.
63. Maisel A.S., Krishnaswamy P., Nowak R.M., McCord J., Hollander J.E., Duc P., Omland T., Storrow A.B., Abraham W.T., Wu A.H., Clopton P., Steg P.G., Westheim A., Knudsen C.W., Perez A., Kazanegra R., Herrmann H.C., McCullough P.A. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 2002, 347:161-167.
64. Martin F.L., Sangaralingham S.J., McKie P.M., Huntley B.K., Harders G.E., Chen H.H., Burnett J.C. Prevention of cardiorenal fibrosis and suppression of proteinuria and aldosterone activation following experimental myocardial infarction with the novel natriuretic peptide CD-NP. J. Card. Fail. 2009, 15:S3.
65. McDonagh T.A., Robb S.D., Murdoch D.R., Morton J.J., Ford I., Morrison C.E., Tunstall-Pedoe H., McMurray J.J., Dargie H.J. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998, 351:9-13.
66. McMurray J.J., Pfeffer M.A. Heart failure. Lancet 2005, 365:1877-1889.
67. Miller M.A., Malkar N.B., Severynse-Stevens D., Yarbrough K.G., Bednarcik M.J., Dugdell R.E., Puskas M.E., Krishnan R., James K.D. Amphiphilic conjugates of human brain natriuretic peptide designed for oral delivery: in vitro activity screening. Bioconjug. Chem. 2006, 17:267-274.
68. Miller W.L., Kurien S., Warfield K.T., Wood C.M., Jaffe A.S. Lack of association between worsening renal function and mortality in heart failure patients treated with nesiritide. Int. J. Cardiol. 2008, 126:234-239.
69. Misono K.S., Ogawa H., Qiu Y., Ogata C.M. Structural studies of the natriuretic peptide receptor: a novel hormone-induced rotation mechanism for transmembrane signal transduction. Peptides 2005, 26:957-968.
70. Murthy K.S., Makhlouf G.M. Identification of the G protein-activating domain of the natriuretic peptide clearance receptor (NPR-C). J. Biol. Chem. 1999, 274:17587-17592.
71. Nesher M., Vachutinsky Y., Fridkin G., Schwarz Y., Sasson K., Fridkin M., Shechter Y., Lichtstein D. Reversible pegylation prolongs the hypotensive effect of atrial natriuretic peptide. Bioconjug. Chem. 2008, 19:342-348.
72. Neuser D., Bellemann P. Receptor binding, cGMP stimulation and receptor desensitization by atrial natriuretic peptides in cultured A10 vascular smooth muscle cells. FEBS Lett. 1986, 209:347-351.
73. Ng L.L., Geeranavar S., Jennings S.C., Loke I., O'Brien R.J. Diagnosis of heart failure using urinary natriuretic peptides. Clin. Sci. 2004, 106:129-133.
74. Nilsson B.L., Soellner M.B., Raines R.T. Chemical synthesis of proteins. Annu. Rev. Biophys. Biomol. Struct. 2005, 34:91-118.
75. Ogawa H., Qiu Y., Ogata C.M., Misono K.S. Crystal structure of hormone-bound atrial natriuretic peptide receptor extracellular domain: rotation mechanism for transmembrane signal transduction. J. Biol. Chem. 2004, 279:28625-28631.
76. Pandey K.N., Nguyen H.T., Sharma G.D., Shi S.J., Kriegel A.M. Ligand-regulated internalization, trafficking, and down-regulation of guanylyl cyclase/atrial natriuretic peptide receptor-A in human embryonic kidney 293 cells. J. Biol. Chem. 2002, 277:4618-4627.
77. Pandey K.N., Pavlou S.N., Inagami T. Identification and characterization of three distinct atrial natriuretic factor receptors. Evidence for tissue-specific heterogeneity of receptor subtypes in vascular smooth muscle, kidney tubular epithelium, and Leydig tumor cells by ligand binding, photoaffinity labeling, and tryptic proteolysis. J. Biol. Chem. 1988, 263:13406-13413.
78. Potter L.R., Yoder A.R., Flora D.R., Antos L.K., Dickey D.M. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb. Exp. Pharmacol. 2009, 191:341-366.
79. Qiu Y., Ogawa H., Miyagi M., Misono K.S. Constitutive activation and uncoupling of the atrial natriuretic peptide receptor by mutations at the dimer interface. Role of the dimer structure in signalling. J. Biol. Chem. 2004, 279:6115-6123.
80. Richards A.M., Lainchbury J.G., Nicholls M.G., Cameron A.V., Yandle T.G. Dendroaspis natriuretic peptide: endogenous or dubious?. Lancet 2002, 359:5-6.
81. Sackner-Bernstein J.D., Kowalski M., Fox M., Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005, 293:1900-1905.
82. Sackner-Bernstein J.D., Skopicki H.A., Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005, 111:1487-1491.
83. Saito Y., Nakao K., Nishimura K., Sugawara A., Okumura K., Obata K., Sonoda R., Ban T., Yasue H., Imura H. Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function. Circulation 1987, 76:115-124.
84. Schirger J.A., Heublein D.M., Chen H.H., Lisy O., Jougasaki M., Wennberg P.W., Burnett J.C. Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo Clin. Proc. 1999, 74:126-130.
85. Schultz H.D., Gardner D.G., Deschepper C.F., Coleridge H.M., Coleridge J.C. Vagal C-fiber blockade abolishes sympathetic inhibition by atrial natriuretic factor. Am. J. Physiol. 1988, 255:R6-R13.
86. Schweitz H., Vigne P., Moinier D., Frelin C., Lazdunski M. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J. Biol. Chem. 1992, 267:13928-13932.
87. Scriven T.A., Burnett J.C. Effects of synthetic atrial natriuretic peptide on renal function and renin release in acute experimental heart failure. Circulation 1985, 72:892-897.
88. Shimekake Y., Kawabata T., Nakamura M., Nagata K. The role of the C-terminal region of rat brain natriuretic peptide in receptor selectivity. FEBS Lett. 1992, 309:185-189.
89. St Pierre L., Flight S., Masci P.P., Hanchard K.J., Lewis R.J., Alewood P.F., de Jersey J., Lavin M.F. Cloning and characterisation of natriuretic peptides from the venom glands of Australian elapids. Biochimie 2006, 88:1923-1931.
90. St-Louis J., Schiffrin E.L. Vasorelaxant effects of and receptors for atrial natriuretic peptides in the mesenteric artery and aorta of the rat. Can. J. Physiol. Pharmacol. 1988, 66:951-956.
91. Steiner A.L., Pagliara A.S., Chase L.R., Kipnis D.M. Radioimmunoassay for cyclic nucleotides. II. Adenosine 3',5'-monophosphate and guanosine 3',5&prime-monophosphate in mammalian tissues and body fluids. J. Biol. Chem. 1972, 247:1114-1120.
92. Steiner A.L., Parker C.W., Kipnis D.M. Radioimmunoassay for cyclic nucleotides. I. Preparation of antibodies and iodinated cyclic nucleotides. J. Biol. Chem. 1972, 247:1106-1113.
93. Stingo A.J., Clavell A.L., Aarhus L.L., Burnett J.C. Cardiovascular and renal actions of C-type natriuretic peptide. Am. J. Physiol. 1992, 262:H308-H312.
94. Sudoh T., Kangawa K., Minamino N., Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988, 332:78-81.
95. Sudoh T., Minamino N., Kangawa K., Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem. Biophys. Res. Commun. 1990, 168:863-870.
96. Suga S., Nakao K., Hosoda K., Mukoyama M., Ogawa Y., Shirakami G., Arai H., Saito Y., Kambayashi Y., Inouye K., et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology 1992, 130:229-239.
97. Suwa M., Seino Y., Nomachi Y., Matsuki S., Funahashi K. Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy. Circ. J. 2005, 69:283-290.
98. Suzuki S., Takeshita A., Imaizumi T., Hirooka Y., Yoshida M., Nakamura M. Evidence against the central nervous system being involved in altered reflex control of sympathetic nerve activity by atrial natriuretic peptide. Brain Res. 1989, 485:109-114.
99. Takagi G., Kiuchi K., Endo T., Yamamoto T., Sato N., Nejima J., Takano T. Alpha-human atrial natriuretic peptide, carperitide, reduces infarct size but not arrhythmias after coronary occlusion/reperfusion in dogs. J. Cardiovasc. Pharmacol. 2000, 36:22-30.
100. Tallarida G., Iellamo F., Raimondi G., Legramante J.M., Cassarino S., Marazza D., Di Nardo P., Peruzzi G. On the role of neural mechanisms in the cardiocirculatory inhibitory action of alpha-human atrial natriuretic peptide in the anesthetized rabbit. J. Hypertens. 1991, 9:935-945.
101. Thomas C.J., Allen A.M., McAllen R.M., Woods R.L. ANP potentiates nonarterial baroreflex bradycardia: evidence from sinoaortic denervation in rats. Auton. Neurosci. 2002, 97:89-98.
102. Thomas C.J., Head G.A., Woods R.L. ANP and bradycardic reflexes in hypertensive rats: influence of cardiac hypertrophy. Hypertension 1998, 32:548-555.
103. Thomas C.J., May C.N., Sharma A.D., Woods R.L. ANP, BNP, and CNP enhance bradycardic responses to cardiopulmonary chemoreceptor activation in conscious sheep. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001, 280:R282-R288.
104. Thomas C.J., Rankin A.J., Head G.A., Woods R.L. ANP enhances bradycardic reflexes in normotensive but not spontaneously hypertensive rats. Hypertension 1997, 29:1126-1132.
105. Thompson D.K., Garbers D.L. Dominant negative mutations of the guanylyl cyclase-A receptor. Extracellular domain deletion and catalytic domain point mutations. J. Biol. Chem. 1995, 270:425-430.
106. van den Akker F., Zhang X., Miyagi M., Huo X., Misono K.S., Yee V.C. Structure of the dimerized hormone-binding domain of a guanylyl-cyclase-coupled receptor. Nature 2000, 406:101-104.
107. Waldman S.A., Rapoport R.M., Murad F. Atrial natriuretic factor selectively activates particulate guanylate cyclase and elevates cyclic GMP in rat tissues. J. Biol. Chem. 1984, 259:14332-14334.
108. Wang W., Ou Y., Shi Y. AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure. Pharm. Res. 2004, 21:2105-2111.
109. Watt V.M., Yip C.C. HeLa cells contain the atrial natriuretic peptide receptor with guanylate cyclase activity. Biochem. Biophys. Res. Commun. 1989, 164:671-677.
110. Wei C.M., Aarhus L.L., Miller V.M., Burnett J.C. Action of C-type natriuretic peptide in isolated canine arteries and veins. Am. J. Physiol. 1993, 264:H71-H73.
111. Wei C.M., Kim C.H., Miller V.M., Burnett J.C. Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide. J. Clin. Invest. 1993, 92:2048-2052.
112. Wijeyaratne C.N., Moult P.J. The effect of alpha human atrial natriuretic peptide on plasma volume and vascular permeability in normotensive subjects. J. Clin. Endocrinol. Metab. 1993, 76:343-346.
113. Wilson E.M., Chinkers M. Identification of sequences mediating guanylyl cyclase dimerization. Biochem. (Mosc.) 1995, 34:4696-4701.
114. Witteles R.M., Kao D., Christopherson D., Matsuda K., Vagelos R.H., Schreiber D., Fowler M.B. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial. J. Am. Coll. Cardiol. 2007, 50:1835-1840.
115. Woodard G.E., Rosado J.A., Brown J. Dendroaspis natriuretic peptide-like immunoreactivity and its regulation in rat aortic vascular smooth muscle. Peptides 2002, 23:23-29.
116. Woods R.L., Anderson W.P. Atrial natriuretic peptide infusion causes vasoconstriction after autonomic blockade in conscious dogs. Am. J. Physiol. 1990, 259:R813-R822.
117. Woods R.L., Oliver J.R., Korner P.I. Direct and neurohumoral cardiovascular effects of atrial natriuretic peptide. J. Cardiovasc. Pharmacol. 1989, 13:177-185.
118. Wu C., Wu F., Pan J., Morser J., Wu Q. Furin-mediated processing of Pro-C-type natriuretic peptide. J. Biol. Chem. 2003, 278:25847-25852.
119. Wu F., Yan W., Pan J., Morser J., Wu Q. Processing of pro-atrial natriuretic peptide by corin in cardiac myocytes. J. Biol. Chem. 2002, 277:16900-16905.
120. Yan W., Wu F., Morser J., Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:8525-8529.
121. Yancy C.W., Krum H., Massie B.M., Silver M.A., Stevenson L.W., Cheng M., Kim S.S., Evans R. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial. Circ. Heart Fail. 2008, 1:9-16.
122. Yandle T.G., Richards A.M., Nicholls M.G., Cuneo R., Espiner E.A., Livesey J.H. Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. Life Sci. 1986, 38:1827-1833.
123. Yasue H., Yoshimura M., Sumida H., Kikuta K., Kugiyama K., Jougasaki M., Ogawa H., Okumura K., Mukoyama M., Nakao K. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994, 90:195-203.
124. Yoshimura M., Yasue H., Morita E., Sakaino N., Jougasaki M., Kurose M., Mukoyama M., Saito Y., Nakao K., Imura H. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1991, 84:1581-1588.